Harnessing Monocytes for a Liposomal Rosiglitazone-Mediated Anti-Inflammatory Effect
Rosiglitazone, an anti-diabetic drug used for treating type Ⅱ diabetes mellitus with known anti-inflammatory properties, was withdrawn from the European market. The United States Food and Drug Administration has restricted its use due to its severe cardiovascular adverse effects. We hypothesized tha...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Andover House Inc.
2022-09-01
|
| Series: | Precision Nanomedicine |
| Online Access: | https://precisionnanomedicine.com/article/38312-harnessing-monocytes-for-a-liposomal-rosiglitazone-mediated-anti-inflammatory-effect |